Paolo Tarantino: Discussion on novel treatment strategies for HR+/HER2- MBC
Paolo Tarantino shared on LinkedIn:
“f you’re attending ESMO24 Barcelona, make sure to join Dr. Javier Cortés Castán, Aditya Bardia, Prof. Dr. med. Sibylle Loibl and myself for a comprehensive discussion on novel treatment strategies for HR+/HER2- MBC!”
Read further.
Source: Paolo Tarantino/LinkedIn
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.